Effects of trastuzumab combined with docetaxel and tegio on serum tumor markers and apoptosis factors in recurrent and metastatic breast cancer
Objective To observe the effect of trastuzumab combined with docetaxel and tegeol on serum tumor markers and apoptosis factors in recurrent and metastatic breast cancer.Methods A total of 86 patients with recurrent and metastatic breast cancer admitted to Xi'an International Medical Center Hospital from August 2020 to August 2023 were selected and divided into the study group and the control group according to the random number table method,43 patients in each group.The control group was treated with docetaxel and tegeol.The study group was combined with trastuzumab on the basis of the control group,then compare the clinical efficacy of the two groups.Results The total effective rate and KPS score of the study group were higher than those of the control group,and the levels of cyclooxygenase-2(COX-2),decoy receptor 3(DcR3),carbohydrate antigen 153(CA153),breast cancer susceptibility gene 1(BRCA1),vascular endothelial growth factor(VEGF)and carcinoembryonic antigen(CEA)were lower than those of the control group,and the progression free survival period was longer than that of the control group(P＜0.05).Conclusion Trastuzumab combined with docetaxel and tegeol is effective in the treatment of recurrent and metastatic breast cancer,which can effectively reduce the expression of tumor markers,vascular endothelial factor and apoptosis factor,improve the quality of life and immune function of patients,and have higher clinical efficacy and safety.
NtrastuzumabDocetaxelTegioRecurrent and metastatic breast cancerTumor markersApoptosis factorVascular endothelial factor
万方数据
维普
